Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

[1]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[2]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[3]  J A Frank,et al.  MRI T2 lesion burden in multiple sclerosis , 2006, Neurology.

[4]  F. Barkhof,et al.  MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study , 2006, The Lancet Neurology.

[5]  L. Kappos,et al.  Predictors of relapse rate in MS clinical trials , 2005, Neurology.

[6]  L. Kappos,et al.  Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization , 2005, Multiple sclerosis.

[7]  À. Rovira,et al.  Is optic neuritis more benign than other first attacks in multiple sclerosis? , 2005, Annals of neurology.

[8]  P. O'Connor.  The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. , 2003, Clinical therapeutics.

[9]  F. Barkhof,et al.  Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a , 2003, Annals of neurology.

[10]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.

[11]  Jeffrey A. Cohen,et al.  Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy , 2002, Multiple sclerosis.

[12]  S. Cole,et al.  Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses , 2002 .

[13]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS , 2001, Multiple sclerosis.

[14]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[15]  G. Barker,et al.  Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .

[16]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[17]  J. Hillert,et al.  Optic neuritis , 1998, Neurology.

[18]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[19]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[20]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[21]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[22]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[23]  S. Cole,et al.  Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. , 2002, Annals of neurology.

[24]  J L Keltner,et al.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. , 1992, The New England journal of medicine.